• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension

byConstance Wu
April 25, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. While chlorthalidone is the recommended thiazide diuretic treatment for hypertension, it has no added benefits compared to hydrochlorothiazide and has significantly worse safety profile.

Evidence Rating Level: 1 (Excellent)

The American College of Cardiology/American Heart Association hypertension guideline reported in 2017 that the recommended thiazide diuretic treatment for hypertension is currently chlorthalidone. However, there are insufficient trials investigating risks and benefits. This Large-Scale Evidence Generation and Evaluation in a Network of Databases (LEGEND) observational, comparative cohort study sought to investigate the cardiovascular and safety outcomes of chlorthalidone and hydrochlorothiazide as first-line treatments for hypertension. Of 730,225 individuals (M [SD] age, 51.5 [13.3] years, 61.6% female), 36,918 were prescribed chlorthalidone with 149 composite outcome events and 693,337 were prescribed hydrochlorothiazide with 3,089 composite outcome events. No significant differences were found in associated risks of stroke, hospitalized heart failure, or myocardial infarction. The hazard ratio for composite cardiovascular outcomes was 1.00 for chlorthalidone compared to hydrochlorothiazide (95% CI 0.85 to 1.17). Chlorthalidone was associated with significantly elevated risks of type 2 diabetes (HR, 1.21, 95% CI 1.12-1.30), chronic kidney disease (HR, 1.24, 95% CI 1.09 to 1.42), acute renal failure (HR, 1.37, 95% CI 1.15 to 1.63), hyponatremia (HR, 1.31, 95% CI 1.16 to 1.47), and hypokalemia (HR, 2.72, 95% CI 2.38 to 3.12). However, chlorthalidone was also associated with a lower risk of abnormal weight gain (HR, 0.73, 95% CI 0.61 to 0.86). This study highlights concerns related to the preferred treatment for hypertension, such that chlorthalidone use not only resulted in non-significant cardiovascular benefits compared to hydrochlorothiazide but was associated with significantly greater risks of metabolite and renal abnormalities.

Click to read the study in JAMA Internal Medicine

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

Tags: chlorthalidoneHigh Blood Pressurehydrochlorothiazidehypertension
Previous Post

Lung ultrasound may be useful in managing children with COVID-19

Next Post

Adverse neurodevelopmental outcomes linked to prenatal exposure to antidepressants

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Hypotension- and hypertension-avoidance strategies may yield similar neurocognitive outcomes following noncardiac surgery

June 14, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Chronic Disease

Maternal hypertension associated with adverse neurodevelopment outcomes in preterm infants

May 10, 2025
#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death
StudyGraphics

#VisualAbstract: Sotatercept Improves Outcomes in Patients with Pulmonary Arterial Hypertension at High Risk for Death

April 17, 2025
Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

App-based physical activity intervention may have a limited role among women with prior hypertensive pregnancy disorder

April 11, 2025
Next Post
Large proportion of late preterm infants and older admitted to the NICU

Adverse neurodevelopmental outcomes linked to prenatal exposure to antidepressants

Radiological findings of COVID-19 pneumonia in Wuhan, China

SARS-CoV-2 epidemiology in the Icelandic population

#VisualAbstract: Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

#VisualAbstract: Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.